Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04056442
Recruitment Status : Recruiting
First Posted : August 14, 2019
Last Update Posted : August 14, 2019
Sponsor:
Information provided by (Responsible Party):
Stero Biotechs Ltd.

Brief Summary:

Treatment will start with dose escalation in addition to Standard of Care (steroid therapy with or without additional therapies) .

At the conclusion of the dose escalation segment of the study, if the 300 mg Cannabidiol dose level/placebo is deemed safe for two weeks with Standard of care dose of steroids, patients will continue receiving this 300 mg dose/placebo for an additional period of 3 months. Weekly tapering off of steroids will then commence and will be carried out .

Three months after starting treatment with Cannabidiol an interim analysis to evaluate Cannabidiol's safety and efficacy will be carried out and treatment assignment group may be changed (according to response confirmation)


Condition or disease Intervention/treatment Phase
Steroid Dependent Crohn's Disease Drug: Cannabidiol , synthetic form Drug: Placebo Phase 2

Detailed Description:

Individual patient Standard of Care (steroid therapy with or without additional therapies) will be administered in a stable fashion during the first weeks of the study in addition to increasing doses of Cannabidiol or placebo ( in a double blind manner. Dosage of Cannabidiol will start at 25 mg twice a day and will be increased every two days, if no side effects are observed, to 50 mg twice a day, 100 mg twice a day and finally to 150 mg twice a day Cannabidiol respectively. Treatment will be given with food. Identical placebo will be administered in the placebo arm. In stage 1,both patient and investigator will be blinded to treatment modalities.

At the conclusion of the dose escalation segment of the study, if the 300 mg Cannabidiol dose level/placebo is deemed safe for two weeks with Standard of care dose of steroids, patients will continue receiving this 300 mg dose/placebo for an additional period of 3 months. Weekly tapering off of steroids will then commence and will be carried out .

Three months after starting treatment with Cannabidiol an interim analysis to evaluate Cannabidiol's safety and efficacy will be carried out by an independent assessor not associated with the study .At the conclusion of this interim analysis, Cannabidiol Non-responders will be removed from the trial, and Placebo Non-responders will be switched over to Cannabidiol.

If a patient flares, then his/her code will be opened by the unblinded observer. If the subject has been administered placebo, then he/she will be crossed over to the Cannabidiol arm. If the subject has been administered Cannabidiol, then he/she will be restarted on Standard of care prednisone in addition to Cannabidiol or removed from study, depending on the severity of the flare-up.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:

Patients will be randomized at a 2:1 Cannabidiol:placebo ratio. After 3 month of treatment a blinded assessor will assess the patient response.

Cannabidiol Non-responders will be removed from the trial, and Placebo Non-responders will be switched over to Cannabidiol

Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients
Actual Study Start Date : July 7, 2019
Estimated Primary Completion Date : July 7, 2021
Estimated Study Completion Date : July 7, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Experimental: Cannabidiol
300 mg Cannabidiol (synthetic form) Olive Oil Solution, 5%
Drug: Cannabidiol , synthetic form
Cannabidiol ( synthetic form)

Drug: Placebo
Olive Oil Solution, 5%

Placebo Comparator: Placebo
Olive Oil Solution
Drug: Placebo
Olive Oil Solution, 5%




Primary Outcome Measures :
  1. Assessment of the safety and tolerability of up to 300 mg CBD/day measured by Adverse Events [ Time Frame: 12 month ]
    significance of the difference in percent of subjects experienced any Adverse events, drug-related Adverse events and Serious Adverse events between the study groups

  2. Efficacy will be mesursed by precentegae of reduction in dose of steroids without flares [ Time Frame: 12 month ]
    50% reduction in dose of steroids without flares


Secondary Outcome Measures :
  1. Percentage of patients without flares [ Time Frame: 12 month ]
    Disease flare will be recorded during the study

  2. Percent of patients who did not demonstrate an increase in inflammatory activity [ Time Frame: 12 month ]
    inflammatory activity scored will be measured during the study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with biopsy confirmed, active, steroid dependent CD, without nutrient absorbance problems (Definition of steroid dependency: CD being treated with at least 5 mg/day steroids for the last 3 months; an attempt to reduce the dose induces flare of disease as determined by physician assessment).
  2. Age ≥18 years
  3. Steroid treatment of at least 3 months and stable steroid dose for at least 2 weeks .If thiopurines and/or biologics are also being administered, then must be administered at stable dose(s) for at least 3 months.
  4. Patients will undergo an ECG and QT parameters will be measured for further analysis.
  5. Female subjects who are postmenopausal (absence of menses for ≥ 2 years confirmed by a follicle stimulating hormone test), or who are surgically sterilized may be enrolled. Similarly, women of childbearing potential who had a negative pregnancy test at screening, who are willing to use two medically acceptable methods of contraception for the duration of the study as well as for at least three months after cessation of CBD treatment and who are willing to undergo pregnancy testing according to the study protocol may be enrolled.
  6. Female subjects who are not breast-feeding and who have no intention to breast-feed during the term of the trial and for at least three months after cessation of CBD treatment may be enrolled.
  7. Subject able to provide written informed consent

Exclusion Criteria:

  1. Viral Hepatitis (HAV, HBV, HCV)
  2. HIV
  3. Serious psychiatric or psychological disorders
  4. Active consumption of illicit drugs including cannabis or derivatives for at least 3 months prior to the study
  5. Patients with short bowel syndrome, symptomatic stricture, abscess, recent history (within the previous 3 months) of abdominal surgery, nutrient absorbance problems
  6. Patients whose disease is inaccessible by endoscopy
  7. Patients with significant cardiac, respiratory or active malignance disease (except Basel Cell Carcinoma) comorbidities.
  8. Any uncontrolled infection at time of registration
  9. Renal comorbidity: eGFR < 30 mL/min/1.73 m2 (note: CKD Grade 4 is defined as eGFR 15-29 mL/min/1.73 m2)
  10. Patient who is taking immunomodulatory medications for other indication
  11. Women of child-bearing potential who intend to become pregnant or who are pregnant or breastfeeding

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04056442


Contacts
Layout table for location contacts
Contact: Timna Naftali, Dr. 97297471017 timna.naftali@clalit.org.il

Locations
Layout table for location information
Israel
Meir Medical Center Recruiting
Kfar Saba, Israel
Contact: Timna Naftali, Dr.    97297471017    timna.naftali@clalit.org.il   
Sponsors and Collaborators
Stero Biotechs Ltd.

Layout table for additonal information
Responsible Party: Stero Biotechs Ltd.
ClinicalTrials.gov Identifier: NCT04056442     History of Changes
Other Study ID Numbers: ST-SDCD-01
First Posted: August 14, 2019    Key Record Dates
Last Update Posted: August 14, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Epidiolex
Anticonvulsants